



May 13, 2026

Company name: ROHTO Pharmaceutical Co., Ltd.
Representative: Hidetoshi Segi, President and COO
(Code: 4527 TSE Prime)
Contact: Masaya Saito, Vice President and CFO
(TEL: 06-6758-8223)

Notice of Revision of Dividend Forecast (Dividend Increase)

ROHTO PHARMACEUTICAL CO., LTD. (the “Company”) hereby announces that, in light of the recent trends in business performance, the Company has revised the year-end dividend announced on February 12, 2026, as described below.

The forecast indicated below is also disclosed in the “Consolidated Financial Results for the Fiscal Year Ended March 31, 2026 [Japanese GAAP].”

Revision of Year-end Dividend Forecast.

(1) Details of the revisions

Revision of dividend forecast for the fiscal Year Ending March 31, 2026 (April 1, 2025 to March 31, 2026)

	Annual dividends(yen)		
	2nd quarter-end	Year-end	Total
Previous forecast (Announced on February 12, 2026)		23.00	44.00
Revised forecast		25.00	46.00
Actual results for the current period	21.00		
(Reference) Results for the previous fiscal year (Fiscal year ended March 31, 2026)	16.00	20.00	36.00

(2) Reasons for the revisions

Consistently and continually returning to shareholders the profits earned through business activities is one of our highest priorities. The fundamental policy is to pay a dividend based on results of operations. Based on the earnings forecast for the fiscal year ending March 31, 2026 (April 1, 2025 to March 31, 2026), to enhance the return of profits to shareholders, for said fiscal year, the Company has decided to increase the year-end dividend by 2 yen to 25 yen per share. As such, the total annual dividend will be 46 yen per share

Rohto Pharmaceutical Co., Ltd.